Ken Griffin Cardiff Oncology, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$2.22 - $5.89 $40,404 - $107,198	18,200 Added 92.39%	37,900 $84,000
Q1 2024 May 15, 2024	BUY	$1.46 - $5.91 $27,156 - $109,926	18,600 Added 1690.91%	19,700 $105,000
Q4 2023 Feb 14, 2024	SELL	$0.96 - $1.55 $7,104 - $11,470	-7,400 Reduced 87.06%	1,100 $1,000
Q3 2023 Nov 14, 2023	BUY	$1.38 - $2.18 $11,730 - $18,530	8,500 New	8,500 $11,000
Q1 2023 May 15, 2023	SELL	$1.45 - $2.09 $14,500 - $20,900	-10,000 Reduced 46.3%	11,600 $19,000
Q4 2022 Feb 14, 2023	SELL	$1.22 - $1.66 $60,390 - $82,170	-49,500 Reduced 69.62%	21,600 $30,000
Q3 2022 Nov 14, 2022	BUY	$1.54 - $3.21 $10,010 - $20,865	6,500 Added 10.06%	71,100 $109,000

12.8M

823K

78K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $107M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.